Leissner J, Hohenfellner R, Thüroff J W, Köppen C, Wolf H K
Department of Urology, Johannes Gutenberg University, Mainz, Germany.
Eur Urol. 2001 Apr;39(4):438-45. doi: 10.1159/000052482.
At present, there are no predictors of tumour behaviour for grade (G) 2 pTa transitional cell carcinomas (TCC) of the bladder. Here we analyse the prognostic relevance of histopathological grading and the immunohistochemical detection of p53 and p21/WAF1.
70 patients were newly diagnosed with G2 pTa TCC of the bladder based on transurethral resection specimens. Two pathologists, blinded with respect to the clinical outcome, confirmed the initial grade and subclassified the G2 lesions into G2a and G2b carcinomas based on the degree of nuclear atypia and the number of mitoses. Immunoreactivity for p53 and p21/WAF1 was evaluated semiquantitatively.
There were 52 G2a and 18 G2b tumours, mean follow-up was 49.2 months. Of all patients, 31.4% remained tumour-free, 48.6% recurred with the same tumour grade and stage, and 20.0% showed tumour progression. Patients with G2a tumours developed tumour progression in 13% in contrast to 39% with G2b lesions (p = 0.037). Of 21 p53-positive tumours, 33% (7/21) developed progressive disease, whereas 14% (7/49) of p53-negative patients showed tumour progression (p = 0.102). Neither p21/WAF1 expression alone nor the combination of p53 and p21/WAF1 correlated with clinical outcome.
The more detailed grading system but not p53 or p21/WAF1 immunohistochemistry was found to be an independent prognostic factor for tumour progression.
目前,对于膀胱2级(G2)pTa期移行细胞癌(TCC)尚无肿瘤行为预测指标。在此,我们分析组织病理学分级以及p53和p21/WAF1免疫组化检测的预后相关性。
基于经尿道切除标本,70例患者被新诊断为膀胱G2 pTa TCC。两名对临床结果不知情的病理学家确认初始分级,并根据核异型程度和有丝分裂数量将G2病变进一步分为G2a和G2b癌。对p53和p21/WAF1的免疫反应性进行半定量评估。
有52例G2a肿瘤和18例G2b肿瘤,平均随访49.2个月。所有患者中,31.4%无肿瘤复发,48.6%以相同肿瘤分级和分期复发,20.0%出现肿瘤进展。G2a肿瘤患者中13%发生肿瘤进展,而G2b病变患者为39%(p = 0.037)。在21例p53阳性肿瘤中,33%(7/21)发生疾病进展,而p53阴性患者中有14%(7/49)出现肿瘤进展(p = 0.102)。单独的p21/WAF1表达以及p53和p21/WAF1的联合表达均与临床结果无关。
发现更详细的分级系统而非p53或p21/WAF1免疫组化是肿瘤进展的独立预后因素。